Position in CYTK
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$4,943
-$8,146 QoQ
Shares Held
75
-63.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2022
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CYTK Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Elequin Capital, LP holds $8,088 across 7 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NKTR |
Nektar Therapeutics
|
56 | $3,909 | |
| 2 | VRDN |
Viridian Therapeutics, Inc.\DE
|
71 | $1,304 | |
| 3 | ASND |
Ascendis Pharma A/S
|
4 | $1,066 | |
| 4 | TVTX |
Travere Therapeutics, Inc.
|
16 | $908 | |
| 5 | INVA |
Innoviva, Inc.
|
36 | $817 | |
| 6 | SRPT |
Sarepta Therapeutics, Inc.
|
3 | $53 | |
| 7 | IMCR |
Immunocore Holdings plc
|
1 | $31 |
All Filings in CYTK
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,943 | 75 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $13,089 | 206 | Shares | Sole | 2026-02-17 | |
| 2024-12-31 | $9,737 | 207 | Shares | Sole | 2025-02-18 | |
| 2024-09-30 | $7,920 | 150 | Shares | Sole | 2024-11-14 | |
| 2023-06-30 | $8,415 | 258 | Shares | Sole | 2023-08-14 | |
| 2022-09-30 | $12,839 | 265 | Shares | Sole | 2022-11-10 | |
| No filing history on record for this holder in this stock. | ||||||